A study from Germany (23) examined different groups of MS patients for MOG antibodies and found a rate of 5% MOG-antibody positivity in a group selected for “NMOSD-type presentations” with severe optic neuritis, myelitis and brainstem presentations. This evidence concerns the gene MOG and myeloid sarcoma.